ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions
  • Abstract Number: 0205

    Cardiovascular Event Risks Among Members with Rheumatoid Arthritis, Psoriatic Arthritis, and Systemic Lupus Erythematosus
  • Abstract Number: 0206

    Urate Lowering Therapy to Acute Treatment Ratio (ULTrA) Index – a Novel Quality Indicator Associated with Reduced Hospital Admissions for Gout
  • Abstract Number: 0207

    Investigation of Delays in Cancer Screening in RA
  • Abstract Number: 0208

    Unlocking COVID-19 Vaccination Choices in Rheumatoid Arthritis: Insights from a Monocentric Study
  • Abstract Number: 0209

    Characteristics of Ordering Providers and Patients with Positive Antinuclear Antibodies: A Pragmatic, Risk Model Study
  • Abstract Number: 0210

    Rheumatology, Heal Thyself: The Experience of Underrepresented Physicians in Rheumatology
  • Abstract Number: 0211

    Characteristics of Hospitalizations and Outpatient Follow-up for Patients with SLE at an Academic Hospital Setting in Austin, Texas
  • Abstract Number: 0212

    Costs of Hospitalization in Patients with SLE: An Analysis of the National Inpatient Sample
  • Abstract Number: 0213

    Electronic Medical Record Inbox Volume Association with Physician Gender, Physician Burnout, and the COVID-19 Pandemic at an Academic Rheumatology Center
  • Abstract Number: 0214

    Real-World Treatment Patterns of Clinical Practice Guideline Therapies in Rheumatoid Arthritis-Associated Interstitial Lung Disease
  • Abstract Number: 0215

    BP Connect Improves Follow-up of High Blood Pressure in Urban Rheumatology and Non-Rheumatology Clinics
  • Abstract Number: 0216

    Can Immune Checkpoint Inhibitors Safely Combat Cancer in Patients with Rheumatoid Arthritis?
  • Abstract Number: 0217

    Understanding Treatment Goals and Factors Influencing Decisions About Clinical Trial Participation in Lupus Patients from Diverse Backgrounds
  • Abstract Number: 0218

    Incidental Findings on Whole Body 18F-FDG PET/CT in a Rheumatoid Arthritis Clinical Trial Population
  • Abstract Number: 0219

    Differentiation of Nail Psoriasis from Healthy Nails Using Ultrasound: A Cross-Sectional Study with a Novel Nail Matrix Measurement Technique
  • « Previous Page
  • 1
  • …
  • 15
  • 16
  • 17
  • 18
  • 19
  • …
  • 182
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology